腹主动脉内移植物取出术风险:二十年早期结局分析
该研究回顾了2002年至2024年密歇根大学142例晚期腹主动脉内移植物取出术病例,其中因内漏取出100例、因感染取出42例。感染组患者任何并发症(57.1% vs 32.0%;P = .006)、严重并发症(54.8% vs 30.0%;P = .005)及30天死亡率(28.6% vs 14.0%;P = .03)均高于内漏组,且死亡率差异持续至2年(38.1% vs 15.0%;P = .007)。
要点
- 感染组任何并发症57.1%,高于内漏组32.0%(P = .006)。
- 感染组30天死亡率28.6%,高于内漏组14.0%(P = .03)。
- 感染组2年死亡率38.1%,高于内漏组15.0%(P = .007)。
核心结论
- 腹主动脉内移植物取出术无论指征如何均伴随高死亡风险,感染在本队列中带来早期死亡风险。
研究设计与样本
- 回顾性分析密歇根大学2002年1月至2024年1月所有开放主动脉手术,识别晚期(>30天)内移植物取出病例,共142例(内漏100例,感染42例),比较围术期特征与结局,采用多变量logistic回归和Kaplan-Meier生存分析。
主要发现
- 感染组任何并发症57.1% vs 内漏组32.0%(P = .006),严重并发症54.8% vs 30.0%(P = .005)。
- NSQIP预测风险:感染组任何并发症44.9% vs 内漏组35.6%(P < .001),严重并发症35.7% vs 29.2%(P < .001),30天死亡率19.0% vs 7.0%(P = .03)。
- 感染组30天死亡率28.6% vs 内漏组14.0%(P = .03),2年死亡率38.1% vs 15.0%(P = .007)。
- 内移植物类型间未见差异。
- 大多数死亡发生在术后45天内。
临床怎么用
- 为面临内移植物取出的患者提供坦诚的手术风险讨论。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Endovascular aneurysm repair (EVAR) currently comprises more than two-thirds of all abdominal aortic aneurysm repairs in the United States. However, data show that patients are at higher risk for late mortality after EVAR compared with open repair. As the number of aging EVARs grow, so, too, does the number requiring explant. The objective of this work is to highlight perioperative details and outcomes of EVAR explantation to allow physicians to better counsel patients regarding the perioperative risks. METHODS: We abstracted all open aortic procedures performed at the University of Michigan from January of 2002 to January of 2024, from which cases of late aortic endograft explants (>30 days) were identified. We then collected and compared data regarding preoperative demographics and aneurysm-related history, perioperative characteristics, and postoperative course, including explant indication and endograft type using t-test, χ2 test, or their non-parametric counterpart when appropriate. Multivariable logistic regression models were developed to evaluate postoperative complications and 30-day mortality rates. Survival was compared using Kaplan-Meier survival analysis. RESULTS: A total of 142 EVAR explants were evaluated, 100 for endoleak and 42 for infection from 2002 to 2024. Patients with infected endografts were more likely than those with endoleaks to have any complications (57.1% vs 32.0%; P = .006) and serious complications (54.8% vs 30.0%; P = .005). Real-world complications were reflected in National Surgical Quality Improvement Program (NSQIP) estimated risks, with infected endograft patients at a higher predicted NSQIP risk than endoleak patients for any complication (44.9% vs 35.6%; P < .001), serious complication (35.7% vs 29.2%; P < .001), and 30-day mortality (19.0% vs 7.0%; P = .03). No differences were seen based on endograft type. Infected endografts were at higher risk for mortality at 30 days (28.6% vs 14.0%; P = .03). That trend persisted to 2 years (38.1% vs 15.0%; P = .007). Most mortality occurred by postoperative day 45. CONCLUSIONS: EVAR explantation, regardless of indication, places patients at high risk for mortality, with infection conferring early mortality risk in this cohort. This work underscores the need for a candid discussion regarding operative risk with patients facing explantation.
引用
- Huang A, Brown C, Arya S, et al. Understanding the risks of abdominal aortic endograft explantation with early outcomes from two decades of experience. J Vasc Surg. 2025. PMID: 40451342. doi:10.1016/j.jvs.2025.05.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。